These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 26229090)

  • 21. "PEAR-ing" Genomic and Epigenomic Analyses for Cancer Gene Discovery.
    Mack SC; Rich JN; Scacheri PC
    Cancer Discov; 2015 Oct; 5(10):1018-20. PubMed ID: 26429935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.
    Gebauer N; Bernard V; Gebauer W; Thorns C; Feller AC; Merz H
    Leuk Lymphoma; 2015 Jan; 56(1):179-85. PubMed ID: 24679006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis.
    Jardin F; Ruminy P; Bastard C; Tilly H
    Pathol Biol (Paris); 2007 Feb; 55(1):73-83. PubMed ID: 16815642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.
    Ding J; Dirks WG; Ehrentraut S; Geffers R; MacLeod RA; Nagel S; Pommerenke C; Romani J; Scherr M; Vaas LA; Zaborski M; Drexler HG; Quentmeier H
    Haematologica; 2015 Jun; 100(6):801-9. PubMed ID: 25769544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular features of a new human lymphoma cell line carrying both BCL2 and BCL6 gene rearrangements.
    Yonetani N; Akasaka T; Akasaka H; Ohno H; Okuma M; Miura I; Takahashi N; Miyanishi S; Okumura A; Muramatsu M; Fukuhara S
    Oncogene; 1998 Aug; 17(8):971-9. PubMed ID: 9747876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.
    Ottema S; Mulet-Lazaro R; Erpelinck-Verschueren C; van Herk S; Havermans M; Arricibita Varea A; Vermeulen M; Beverloo HB; Gröschel S; Haferlach T; Haferlach C; J Wouters B; Bindels E; Smeenk L; Delwel R
    Nat Commun; 2021 Sep; 12(1):5679. PubMed ID: 34584081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
    Petrich AM; Nabhan C; Smith SM
    Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An aggressive B-cell lymphoma with rearrangements of MYC and CCND1 genes: a rare subtype of double-hit lymphoma.
    Durot E; Patey M; Luquet I; Gaillard B; Kolb B; Delmer A
    Leuk Lymphoma; 2013 Mar; 54(3):649-52. PubMed ID: 22784333
    [No Abstract]   [Full Text] [Related]  

  • 30. The gene for interleukin-21 receptor is the partner of BCL6 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma.
    Ueda C; Akasaka T; Kurata M; Maesako Y; Nishikori M; Ichinohasama R; Imada K; Uchiyama T; Ohno H
    Oncogene; 2002 Jan; 21(3):368-76. PubMed ID: 11821949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of the c-myc p1 promoter in Burkitt's lymphoma by the hs3 immunoglobulin heavy-chain gene enhancer.
    Hu HM; Kanda K; Zhang L; Boxer LM
    Leukemia; 2007 Apr; 21(4):747-53. PubMed ID: 17287852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene.
    Lossos IS; Akasaka T; Martinez-Climent JA; Siebert R; Levy R
    Leukemia; 2003 Jul; 17(7):1390-7. PubMed ID: 12835729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular heterogeneity of B-lineage diffuse large cell lymphoma.
    Volpe G; Vitolo U; Carbone A; Pastore C; Bertini M; Botto B; Audisio E; Freilone R; Novero D; Cappia S; De Giuli P; Mazza U; Resegotti L; Palestro G; Saglio G; Gaidano G
    Genes Chromosomes Cancer; 1996 May; 16(1):21-30. PubMed ID: 9162193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A subtle t(3;8) results in plausible juxtaposition of MYC and BCL6 in a child with Burkitt lymphoma/leukemia and ataxia-telangiectasia.
    Sandlund JT; Kastan MB; Kennedy W; Behm F; Entrekin E; Pui CH; Kalwinsky DT; Raimondi SC
    Cancer Genet Cytogenet; 2006 Jul; 168(1):69-72. PubMed ID: 16772123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rearrangement of the BCL6 gene in B-cell lymphoid neoplasms.
    Muramatsu M; Akasaka T; Kadowaki N; Ohno H; Fukuhara S; Okuma M
    Leukemia; 1997 Apr; 11 Suppl 3():318-20. PubMed ID: 9209377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas.
    Martín-Subero JI; Odero MD; Hernandez R; Cigudosa JC; Agirre X; Saez B; Sanz-García E; Ardanaz MT; Novo FJ; Gascoyne RD; Calasanz MJ; Siebert R
    Genes Chromosomes Cancer; 2005 Aug; 43(4):414-23. PubMed ID: 15852472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TAF Family Proteins and MEF2C Are Essential for Epstein-Barr Virus Super-Enhancer Activity.
    Wang C; Jiang S; Zhang L; Li D; Liang J; Narita Y; Hou I; Zhong Q; Gewurz BE; Teng M; Zhao B
    J Virol; 2019 Aug; 93(16):. PubMed ID: 31167905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular cloning of translocation breakpoint from der(8)t(3;8)(q27;q24) defines juxtaposition of downstream of C-MYC and upstream of BCL6.
    Sonoki T; Tatetsu H; Nagasaki A; Hata H
    Int J Hematol; 2007 Aug; 86(2):196-8. PubMed ID: 17875538
    [No Abstract]   [Full Text] [Related]  

  • 39. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas.
    Hallermann C; Kaune KM; Gesk S; Martin-Subero JI; Gunawan B; Griesinger F; Vermeer MH; Santucci M; Pimpinelli N; Willemze R; Siebert R; Neumann C
    J Invest Dermatol; 2004 Jul; 123(1):213-9. PubMed ID: 15191563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.
    Ott G; Rosenwald A; Campo E
    Blood; 2013 Dec; 122(24):3884-91. PubMed ID: 24009228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.